|
|
Post by Hot Christian Stocks on Jan 24, 2014 9:37:02 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 26, 2014 21:25:02 GMT -5
$NVLX partner Austrianova will present at the international Phacilitate Cell & Gene Therapy Forum 2014 to be held in Washington, DC January 27-29, 2014 SILVER SPRING, Md., Jan. 24, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (OTCQB:NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that Dr. Walter H. Gunzburg, Chairman and Chief Technical Officer of Nuvilex's partner Austrianova, will present at the international Phacilitate Cell & Gene Therapy Forum 2014 to be held in Washington, DC January 27-29, 2014. Dr. Gunzburg is the co-developer of the novel proprietary and patented cell encapsulation technology that Nuvilex expects will have a profound effect on how cancers and diabetes will be treated in the future. In his presentation, Dr. Gunzburg will present data that will explain the nature of the cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™. In addition to discussing the use of this technology for the encapsulation of stem cells, Dr. Gunzburg will speak to its use as a pivotal part of Nuvilex's treatment for advanced, inoperable pancreatic cancer. Dr. Gunzburg will emphasize the results of earlier Phase 1/2 clinical trials using Nuvilex's treatment for this deadly disease. The worldwide exclusive rights to use the Cell-in-a-Box™ technology in developing treatments for pancreatic and all other forms of cancer, as well as for diabetes, were acquired by Nuvilex from SG Austria Pte. Ltd. (Austrianova) and Austrianova Singapore Pte. Ltd., respectively, in 2013. Nuvilex's proprietary pancreatic cancer treatment consists of the combination of low doses of the well-known anti-cancer prodrug ifosfamide with ifosfamide-activating (convert ifosfamide into its "cancer-killing" form) cells that have been encapsulated using the Cell-in-a-Box™ technology. In Phase 1/2 clinical trials in patients with advanced, inoperable pancreatic cancer, Nuvilex's treatment was shown to essentially double the median survival time and percentage of one-year survivors over those seen in historical data for Gemzar® (gemcitabine), the only drug approved to date by the FDA as a single agent for the treatment of the disease. But unlike Gemzar®, Nuvilex's treatment had no serious treatment-related side effects associated with it. The Phacilitate Cell & Gene Therapy Forum is an international three-day event held annually that focuses on business and strategic issues related to the development of cell therapies and related technologies. It is considered the world's leading strategic and partnering event globally for those in the cell and gene therapy sectors. Sponsors of, and participants in, the event include many of the world's major pharmaceutical and biotech companies. Attendees also include major decision makers from those entities, regulatory personnel and others who join to discuss advances, challenges and opportunities in cell and gene therapy. Commenting on Dr. Gunzburg's appearance at, and participation in, next week's international Cell & Gene Therapy Forum, Nuvilex CEO and President, Kenneth L. Waggoner, commented, "Dr. Gunzburg's research and development of the cellulose-based Cell-in-a-Box™ technology may revolutionize the way many experts view how difficult-to-treat cancers will be managed in the future. We're confident that his presentation and involvement in two panel discussions will capture the imaginations of experts at the Forum. We also strongly believe that the work Dr. Gunzburg and his colleagues have already accomplished, together with research Nuvilex is carrying out itself, via its subsidiary Medical Marijuana Sciences and with potential partners, may result in a sea change in the way many deadly and debilitating diseases are approached and treated in the future." www.stockwatch.com/News/Item.aspx?bid=U-z10065366-U%3aNVLX-20140124&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Jan 27, 2014 9:57:39 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 28, 2014 9:37:26 GMT -5
$NVLX contractor, Inno Biologics Sdn. Bhd., is using the Clone-Pix™ technology for the isolation and selection of clones preparatory to obtaining the large numbers of cells for Nuvilex's future clinical trials in advanced, inoperable pancreatic cancer.
Clone-Pix™ is considered to be "state-of–the-art" technology in the cloning process. It is an instrument that allows for the automated isolation of high value clones of mammalian cells. Clone-Pix™ is now employed by more than 100 laboratories and entities throughout the world and is used by notable pharmaceutical and biotech companies such as Merck, GlaxoSmithKline, Wyeth and Genentech. By employing this technology, workflow throughout the cloning process is increased and this allows for more clones to be screened in less time than would be possible using conventional technologies.
Clone-Pix™ allows for the gentle "picking" of clones to ensure high viability of the selected clones. The "best clones" for Nuvilex's purposes will be isolated, tested and propagated to obtain the requisite numbers of cells for cellulose-based encapsulation that will ultimately form part of Nuvilex's treatment for advanced pancreatic cancer. The most desirable of the selected clones will be those that have elevated activity of the enzyme that converts the cancer prodrug ifosfamide into its cancer-killing form.
|
|
|
|
Post by Hot Christian Stocks on Jan 29, 2014 9:36:23 GMT -5
$NVLX - The live-cell encapsulation technology employed by Nuvilex is a way to enclose living cells in protective “cocoons” about the size of the head of a pin - we do not encapsulate drugs, but living cells. Each capsule can enclose approximately 10,000 cells; this number can differ depending upon the size of the cells encapsulated. The cell encapsulation technology used by Nuvilex can be classified as a “platform” upon which treatments for different indications may be built.
Depending on the type of cells used, the encapsulated cells can be employed in developing treatments for serious, debilitating and even deadly diseases. Nuvilex’s primary interests in the use of the live-cell encapsulation technology are for the development of treatments for various cancers and for diabetes.
|
|
|
|
Post by Hot Christian Stocks on Jan 30, 2014 9:19:34 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Jan 31, 2014 9:38:26 GMT -5
$NVLX worldwide exclusive rights for Nuvilex to use Austrianova's Cell-in-a-Box(TM) obligation fulfilled SILVER SPRING, Md., Jan. 30, 2014 (GLOBE NEWSWIRE) -- Nuvilex, Inc. (NVLX), an international biotechnology company providing cell and gene therapy solutions for the treatment of diseases, announced today that it has received its share issuance from SGAustria Pte. Ltd. (Austrianova), who owns Austrianova Singapore Pte. Ltd. (Austrianova Singapore), that equates to a 14.5% equity interest in Austrianova. The issuance of shares by Austrianova fulfils an obligation by Austrianova to Nuvilex that was part of the Asset Purchase Agreement between both companies pertaining to the acquisition of Bio Blue Bird AG and, with it, the worldwide exclusive rights for Nuvilex to use Austrianova's Cell-in-a-Box(TM) cellulose-based live-cell encapsulation technology for the development of treatments for all types of cancer. Nuvilex has also obtained from Austrianova Singapore the exclusive worldwide rights to use the Cell-in-a-Box(TM) technology for the development of treatments for diabetes. Cell-in-a-Box(TM) is a patented technology whereby living cells can be encapsulated in cellulose-based, pin-head-sized, spherical capsules that are bio-inert, but have pores in their outer walls to permit nutrients to enter and nourish the cells inside them and allow waste products and beneficial substances from the cells to leave. The capsules are fully protective of the living cells inside them and can remain intact in the body over long periods of time. The capsules can be easily administered via needles or through catheters. The Cell-in-a-Box(TM) technology has shown success in the treatment of pancreatic cancer when combined with the conventional chemotherapy prodrug ifosfamide administered at much lower doses than when it is used against other cancers; as a consequence, markedly reduced drug-associated side effects were experienced by the patients. The Cell-in-a-Box(TM) technology was developed and matured under the aegis of Professor Walter H. Gunzburg, Chairman and Chief Technical Officer of Austrianova Singapore, and Dr. Brian Salmons, CEO and President of Austrianova Singapore. Over the past several years, an excellent relationship has developed among Professor Gunzburg, Dr. Salmons and Dr. Robert F. Ryan, Nuvilex's Chief Scientific Officer. Nuvilex believes that this fulfilment of the terms of the Asset Purchase Agreement will advance even further the cooperation and collaboration that has developed between the Austrianova companies and Nuvilex. Kenneth L. Waggoner, President and CEO of Nuvilex stated "The receipt of shares by Nuvilex equating to a 14.5% equity interest in Austrianova not only completes the terms of the Asset Purchase Agreement between both companies, but also serves to cement further the excellent working relationships that have developed between our respective companies. We look forward to working closely with Professor Gunzburg, Dr. Salmons and their colleagues at Austrianova as we advance the use of the Cell-in-a-Box(TM) live-cell encapsulation technology in developing treatments for various cancers, for insulin-dependent diabetes and for disease treatments that involve components of marijuana and, in particular, as we prepare for our late-phase clinical trials in advanced pancreatic cancer." finance.yahoo.com/news/nuvilex-nvlx-acquires-14-5-141500674.html?soc_src=mediacontentstory |
|
|
|
Post by Hot Christian Stocks on Feb 3, 2014 9:32:46 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 4, 2014 9:37:06 GMT -5
$NVLX announced subsidiary, Medical Marijuana Sciences, Inc., plans to use the unique and proprietary cellulose-based live-cell encapsulation technology known as Cell-in-a-Box™ to develop treatments for serious and deadly forms of cancer. The revolutionary treatments will deliver cancer-fighting agents based on constituents of Cannabis(marijuana) that are known as cannabinoids. In developing cancer treatments utilizing the Cell-in-a-Box™ live-cell encapsulation technology, living cells that are capable of converting anti-cancer prodrugs into their cancer-killing forms are enclosed in protective cellulose-based, pin-head-sized capsules that are implanted in or near a cancer tumor. Following implantation of the Cell-in-a-Box™ capsules, the anticancer prodrugs are then administered. The combination of the Cell-in-a-Box™ technology with the anti-cancer prodrug ifosfamide has been shown in Phase 1/2 trials conducted in the early 2000s to be extremely effective in treating patients with advanced inoperable pancreatic cancer (see www.nuvilex.com/pancreatic-cancer). When the data from those trials were compared with historical data for Gemzar® (the only drug approved to date by the FDA as a single agent for the treatment of advanced pancreatic cancer), the median survival time was increased to 11 months (from 5.7 months for Gemzar®) using Nuvilex's treatment and the one-year survival rate with Nuvilex's treatment (36%) was double that seen with Gemzar®(18%). Tumor sizes were also reduced from 25-50% in 4 out of 14 patients and no serious treatment-related side-effects were experienced by any of the patients using the Cell-in-a-Box™ plus ifosfamide combination. This is because only one-third the dose of ifosfamide normally employed in treating other forms of cancer was used in the trials due to the unique nature of the Cell-in-a-Box delivery system. In 2013, Nuvilex acquired exclusive worldwide and patented rights to use this cellulose-based encapsulation technology for the development of treatments for all forms of cancer. Medical Marijuana Sciences intends to take advantage of the opportunity to employ the Cell-in-a-Box™ encapsulation technology together with constituents of Cannabis for the development of treatments for some of the deadliest and most difficult-to-treat forms of cancer, such as gliomas (a type of brain cancer) and pancreatic cancer. The type of cells encapsulated using the Cell-in-a-Box™ live-cell encapsulation technology will be those that optimize the effectiveness and safety of naturally-occurring cannabinoids against such cancers in the same way that the technology was used in developing a unique treatment for pancreatic cancer. Dr. Mark L. Rabe, Chairman of Medical Marijuana Sciences' Scientific Advisory Board commented, "Reputable scientific journals contain numerous reports that confirm the anti-cancer properties of cannabinoids. Initial trials have also documented the effectiveness of treating pancreatic cancer using the Cell-in-a-Box™ live-cell encapsulation technology. When taken along with the fact that Medical Marijuana Sciences' parent company, Nuvilex, owns the exclusive worldwide rights to utilize this technology in developing cancer treatments, we believe that Medical Marijuana Sciences is in a unique position to develop cannabinoid-based treatments for cancer that will set it far apart from others in the medical marijuana arena." www.stockwatch.com/News/Item.aspx?bid=U-z10066623-U%3aNVLX-20140203&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Feb 5, 2014 9:07:23 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 6, 2014 9:17:32 GMT -5
$NVLX marijuana debate landed on the doorstep of the National Football League (NFL) NEW YORK, NY -- (Marketwired) -- 02/05/14 Nuvilex, Inc. (OTCQB: NVLX) entered the medical marijuana arena in 2013 as a biotech that would use its expertise to develop treatments for hard to treat cancers. The company said it will initially utilize cannabidiol, one of the compounds found in Cannabis, as the basis for developing treatments for some of the deadliest forms of cancer, namely pancreatic cancer and cancers of the brain, that have historically shown they're extremely difficult to treat. In the process of developing treatments for cancers of the brain, the company could find itself as the leader in researching the benefits of medicinal marijuana on concussions. With the Super Bowl just on the big stage, the marijuana debate landed on the doorstep of the National Football League (NFL). When asked, the league's commissioner, Roger Goodell said the NFL would consider allowing athletes to use marijuana to treat concussions and other head injuries if medical experts deemed it a legitimate solution. Pete Carroll, the head coach of the Super Bowl Champion Seattle Seahawks, agrees with the commissioner. Carroll said he is in support of the NFL looking further into whether medicinal marijuana could be beneficial to players. In an ESPN SportsNation Poll answered by more than 66,000 people, 70 percent of those respondents said they too were okay with the NFL approving the use of medicinal marijuana. When it comes to both cancer and diabetes, Nuvilex has exclusive worldwide rights to use Cell-in-a-Box, a live-cell encapsulation technology that targets cancerous tumors, potentially inhibits progression, and treats the tumor at its core. So, while conducting research and developing treatments using Cannabis, Nuvilex and the NFL could find some common ground. Nuvilex is one of the legitimate businesses in the marijuana industry waiting for regulations and nationwide legalization to play itself out in order to remove any legality that may face any company using the drug for medicinal purposes. www.stockwatch.com/News/Item.aspx?bid=U-i1087448-U%3aNVLX-20140205&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Feb 7, 2014 9:32:25 GMT -5
In 2013, Nuvilex acquired exclusive worldwide and patented rights to use this cellulose-based encapsulation technology for the development of treatments for all forms of cancer. Medical Marijuana Sciences intends to take advantage of the opportunity to employ the Cell-in-a-Box™ encapsulation technology together with constituents of Cannabis for the development of treatments for some of the deadliest and most difficult-to-treat forms of cancer, such as gliomas (a type of brain cancer) and pancreatic cancer. The type of cells encapsulated using the Cell-in-a-Box™ live-cell encapsulation technology will be those that optimize the effectiveness and safety of naturally-occurring cannabinoids against such cancers in the same way that the technology was used in developing a unique treatment for pancreatic cancer.
|
|
|
|
Post by Hot Christian Stocks on Feb 10, 2014 9:08:28 GMT -5
$NVLX Cell-in-a-Box technology to develop marijuana-based treatments for cancer
NEW YORK, NY -- (Marketwired) -- 02/10/14If Nuvilex, Inc. (OTCQB: NVLX) can use the Cell-in-a-Box technology to develop marijuana-based treatments for cancer with the same success it has seen in two independent clinical trials to develop a treatment for advanced inoperable pancreatic cancer, then the Cannabis industry is in for some real fireworks. Last week Nuvilex announced it will, in fact, use the unique and proprietary cellulose-based live-cell encapsulation technology, Cell-in-a-Box, to develop treatments for serious and deadly forms of cancer. In the announcement, the company stated the revolutionary treatments will deliver cancer-fighting agents based on constituents of Cannabis known as cannabinoids. Since the company acquired the exclusive worldwide rights to use the technology to develop treatments for all types of cancer, Nuvilex's work with marijuana will include developing treatments for some of the deadliest and most difficult-to-treat forms of cancer, such as gliomas and pancreatic cancer. With late-phase clinical trials in advanced inoperable pancreatic cancer in Nuvilex's future, the company will likely learn a great deal from those trials which will use Cell-in-a-Box combined with the anti-cancer prodrug ifosfamide that it can then apply to its work with cannabinoids. Nuvilex stated that the type of cells encapsulated using Cell-in-a-Box to develop marijuana-based treatments will be those that optimize the effectiveness and safety of naturally-occurring cannabinoids against deadly cancers in the same way the technology was used in developing a unique treatment for pancreatic cancer. Dr. Mark Rabe, is the Chairman of the Scientific Advisory Board for Nuvilex's Cannabis subsidiary, Medical Marijuana Sciences, and he believes that the company is in a unique position to develop cannabinoid-based treatments for cancer that will set it far apart from others in the medical marijuana arena. For those following the Nuvilex story, you're well aware that Cell-in-a-Box has proven it can compete with the likes of Eli Lilly and Celgene in early pancreatic cancer results, so if its past is a prelude to its future, cancer patients could be in very good hands. www.stockwatch.com/News/Item.aspx?bid=U-i1088468-U%3aNVLX-20140210&symbol=NVLX®ion=U |
|
|
|
Post by Hot Christian Stocks on Feb 11, 2014 8:14:41 GMT -5
|
|
|
|
Post by Hot Christian Stocks on Feb 12, 2014 9:07:27 GMT -5
|
|
